Sinopharm's first-quarter results came in slightly below expectations, while quality improvement remains the key theme for 2026

Overview

This report is Morgan Stanley's review of Sinopharm Group (1099.HK)'s 1Q26 results under China GAAP. The company reported 1Q26 revenue of RMB 140.8 billion, down 0.6% YoY, and earnings of RMB 1.414 billion, down 3.0% YoY, slightly below the firm's expectations for first-half revenue and earnings growth of 1.7% and 5.2%, respectively. The report believes short-term growth momentum is limited, especially as pharmaceutical and medical device distribution businesses remain under policy pressure, but undemanding valuation, defensive sentiment, and improving operating quality keep the stock attractive to investors.

Core views

The core judgment is that the results slightly weaken the investment thesis, but do not change the Overweight rating. Pharmaceutical distribution declined slightly, the drop in medical device distribution narrowed, and pharmacy revenue grew by about 5%; gross margin came under pressure from tender-related price cuts and delayed rebates. In 2026, the company's focus is not on high growth, but on optimization measures promoted by the new management, improving financial health, and enhancing pharmacy profitability. At the industry level, medical insurance cost controls, price cuts, and pressure on hospital channels continue to suppress domestic healthcare demand, while retail channels are bottoming out after store closures caused by 2025 medical insurance inspections.

Analysis framework

The report evaluates the company's short-term earnings quality and medium-term valuation attractiveness by combining first-quarter China GAAP financial data, segment revenue trends, gross margin changes, operating cash flow, accounts receivable, and leverage levels, and uses a DCF valuation framework to derive the target price.

Methodology notes

• Valuation methodsDCF

  Discounted cash flow valuation

  Morgan Stanley uses a discounted cash flow approach, assuming a WACC of 10.8%, a terminal growth rate of 2%, and a steady-growth state reached in 10 years.

• modelMorgan Stanley ModelWare

  Morgan Stanley internal model framework

  Unless otherwise stated, the main forecasts and metrics in the report are based on the Morgan Stanley ModelWare framework; metrics marked with double asterisks are based on the consensus methodology.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sinopharm Group（1099.HK）

  Research target

  Strengths

  A leading healthcare distributor in Hong Kong equities with undemanding valuation; improving pharmacy profitability; narrowing operating cash outflow, and improving accounts receivable and leverage levels.

  Weaknesses

  Limited growth in pharmaceutical and device distribution businesses; first-quarter revenue and earnings were slightly below expectations; gross margin was affected by price cuts and delayed rebates.

  Comparison

  The report rates the company's return outlook as Overweight relative to Morgan Stanley's sector coverage, with an Attractive sector view.

  Risks

  Broad price cuts for pharmaceuticals and consumables, escalating anti-corruption efforts in hospitals, medical insurance cost controls, and government reimbursement controls may continue to weigh on industry growth.

• China healthcare sector

  Industry backdrop

  Strengths

  Retail channels are showing signs of bottoming after severe contraction in 2025, and some leaders may benefit from industry consolidation and improving operating quality.

  Weaknesses

  Demand in hospital channels is clearly pressured by medical insurance cost controls and price cuts, with high policy uncertainty.

  Comparison

  Morgan Stanley's view on the China healthcare sector is Attractive.

  Risks

  Price cuts, medical insurance inspections, hospital anti-corruption efforts, and tighter reimbursement policies may drag on industry revenue and margins.

Key data

• 1Q26 revenueRMB 140.8 billionDown 0.6% YoY.
• 1Q26 earningsRMB 1.414 billionDown 3.0% YoY.
• 1Q26 gross margin6.4%Contracted 0.3 percentage points YoY, affected by tender-driven price cuts and delayed manufacturer rebates.
• Management guidance for full-year gross marginabout 7%Management expects full-year gross margin to be similar to 2025.
• Target priceHK$23.00Implies about 20% upside versus the HK$19.22 closing price.
• 2026e EPSRMB 2.50The table shows the 12/26e forecast.
• 2026e P/E6.7xValuation is at a low level, one reason investors remain interested in the stock.
• Accounts receivableRMB 233.5 billionDown 2% YoY.
• Operating cash flowOutflow of RMB 32.2 billionOutflow narrowed 6% YoY.
• Debt-to-asset ratio65.9%Down 2.9 percentage points YoY.

Impact & implications

For investors, these results are more of a short-term negative: revenue and earnings came in slightly below expectations, gross margin is under pressure, and the industry policy environment remains unfriendly. But the medium-term implication is not simply bearish, because the company is not expensively valued, its dividend yield has some appeal, and management is focusing 2026 on operating quality, financial health, and improving pharmacy profitability. If SOE reform, lower interest rates, or improvements in cost and rebate timing materialize, there is still room for valuation recovery.

Risks

• Large-scale price cuts for pharmaceuticals and consumables may continue to compress gross margin.
• If China's anti-corruption campaign in hospitals escalates, it may further suppress industry growth.
• Medical insurance cost controls and government reimbursement controls continue to pressure demand in hospital channels.
• Delayed manufacturer rebates or policy disruptions may cause volatility in earnings recognition timing.
• Distribution business growth is limited; if operating quality improvement falls short of expectations, room for valuation recovery may be constrained.

What to watch

• Whether full-year gross margin can remain around the roughly 7% level expected by management.
• Whether pharmaceutical and medical device distribution revenue continues to post low growth or decline.
• Whether profit improvement at National Accord and the pharmacy business continues.
• Whether accounts receivable, operating cash flow, and leverage ratio continue to improve.
• Changes in SOE reform targets, lower interest rates, and the intensity of policy cost controls.